Search Results

PAVmed Inc. (NASDAQ: PAVM, PAVMZ) (“PAVmed” or the “Company”) today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) (“Lucid”) and Veris Health Inc. (“Veris”), and presented financial results for the Company for the three months ended March 31, 2024.

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed” or the “Company”), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Tuesday, May 14, 2024, at 8:30 AM ET.

PAVmed Inc. today announced that it will host a business update conference call and webcast on Wednesday, March 27, 2024, at 8:30 AM ET.

PAVmed Inc announced that Veris and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, a National Cancer Institute-Designated Comprehensive Cancer Center, launched a pilot program and enrolled the first patients on the Veris Cancer Care Platform™ pursuant to a recently-executed memorandum of understanding.

PAVmed Inc. provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. and Veris Health Inc., and presented financial results for the year ended December 31, 2023.

PAVmed Inc. announced that Veris and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, a National Cancer Institute-Designated Comprehensive Cancer Center, have executed a memorandum of understanding to implement a pilot program where cancer patients would be enrolled on the Veris Cancer Care Platform™.

PAVmed Inc. (NASDAQ: PAVM, PAVMZ) (“PAVmed” or the “Company”) today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) (“Lucid”) and Veris Health Inc. (“Veris”), and presented financial results for the Company for the three and nine months ended September 30, 2023.

PAVmed Inc. announced a dividend of approximately 3.3 million shares of common stock of its majority-owned subsidiary, Lucid Diagnostics Inc., which equals the number of shares PAVmed will receive in the contemporaneous partial settlement of outstanding intercompany debt owed to PAVmed by Lucid.

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed” or the “Company”), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Wednesday, November 15, 2023, at 8:30 AM EST.

PAVmed Inc. (NASDAQ: PAVM, PAVMZ) (“PAVmed” or the “Company”) today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) (“Lucid”) and Veris Health Inc. (“Veris”), and presented financial results for the Company for the three and six months ended June 30, 2023.